key: cord-0922311-muvcxsl6
authors: Fujita, Y.; Hoshina, T.; Matsuzaki, J.; Kadota, T.; Fujimoto, S.; Kawamoto, H.; Watanabe, N.; Sawaki, K.; Sakamoto, Y.; Miyajima, M.; Lee, K.; Nakaharai, K.; Horino, T.; Nakagawa, R.; Araya, J.; Miyato, M.; Yoshida, M.; Kuwano, K.; Ochiya, T.
title: Early Prediction of COVID-19 Severity Using Extracellular Vesicles and Extracellular RNAs
date: 2020-10-16
journal: nan
DOI: 10.1101/2020.10.14.20212340
sha: 3566d56321dc0193adb131ad797b0e8fc8030fe1
doc_id: 922311
cord_uid: muvcxsl6

The clinical manifestations of COVID-19 vary broadly, ranging from asymptomatic infection to acute respiratory failure and death. But the predictive biomarkers for characterizing the variability are still lacking. Since emerging evidence indicates that extracellular vesicles (EVs) and extracellular RNAs (exRNAs) are functionally involved in a number of pathological processes, we hypothesize that these extracellular components may be key determinants and/or predictors of COVID-19 severity. To test our hypothesis, we collected serum samples from 31 patients with mild COVID-19 symptoms at the time of their admission. After standard therapy without corticosteroids, 9 of the 31 patients developed severe COVID-19 symptoms. We analyzed EV protein and exRNA profiles to look for correlations between these profiles and COVID-19 severity. Strikingly, we identified three distinct groups of markers (antiviral response-related EV proteins, coagulation-related markers, and liver damage-related exRNAs) with the potential to serve as early predictive biomarkers for COVID-19 severity. Among these markers, EV COPB2 has the best predictive value for severe deterioration of COVID-19 patients in this cohort. This type of information concerning functional extracellular component profiles could have great value for patient stratification and for making early clinical decisions about strategies for COVID-19 therapy.

1 5 0 with respect to age, smoking index, and levels of CRP and ALT (P <0.05). We selected 1 5 1 these 4 parameters for Pearson's correlation analysis to identify correlations between 1 5 2 the three groups in terms of age, smoking index, CRP, and ALT ( Figure S1b ). There . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted October 16, 2020. .

We performed receiver operating characteristic (ROC) analysis on combined 1 5 8

Group1 and Group 2 to provide a robust test of sensitivity, specificity, and area under Based on the ROC analysis, optimal cutoffs for the 4 parameters were 1 6 6 identified via use of the Youden index (Table S6) . For further analysis, we used these 1 6 7 cutoffs to separate COVID-19 patients into low and high groups for comparing the for each of the four parameters to compare the high and low groups for time-to-onset of progression-free times for age and CRP were significantly shorter in the high group than 1 7 2 in the low group (P=3.9×10 -6 ; P=0.014, respectively). These findings suggest that the . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) identified 1676 proteins, following exclusion of proteins that were not present in all 1 9 1 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted October 16, 2020. . https://doi.org/10.1101/2020.10.14.20212340 doi: medRxiv preprint 1 4 samples. Of these 1676 proteins, a total 723 proteins were present at different levels between the three groups (Figure 1b) . This differentiation could be described by the Although a little overlap or dispersity was demonstrated, we found obvious EV 2 0 2 proteomic differences between Group 1 and Group 2 in the PCA scores plot. To further identify differences in EV proteins from Group 1 and Group 2 2 0 4 patients, a cross-validation score 17 , which indicates the robustness of discrimination proteins with cross-validation scores >0.75 (Table S4) . Further, we show the abundance 2 0 8 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted October 16, 2020. . https://doi.org/10.1101/2020.10.14.20212340 doi: medRxiv preprint from degradation by incorporation into EVs or by association with lipids and/or proteins. for these 43 transcripts among the three groups, we performed unsupervised trend toward separation between the three groups (Figure 2b ). This separation could be 2 5 9

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted October 16, 2020. . https://doi.org/10.1101/2020.10.14.20212340 doi: medRxiv preprint Moreover, despite some overlap or dispersity, the PCA plots allow us to detect obvious 2 6 3 differences in exRNA profiles between Group 1 and Group 2. For discrimination between Group 1 and Group 2, a cross-validation score expression in Group 2 than in uninfected controls or Group 1 (P trend <0.05). . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted October 16, 2020. . https://doi.org/10.1101/2020.10.14.20212340 doi: medRxiv preprint 1 9

Predictive value of 6 exRNAs for COVID-19 severity 2 7 7

Next, we constructed ROC curves for Group1 and Group 2 to provide a robust 2 7 8

test of sensitivity, specificity, and AUC values for our set of 6 predictive exRNA Additional ROC curves were generated to identify optimal cutoff values for 2 8 6 the 6 transcripts according to the Youden index ( a severe event after admission were analyzed for each of the 6 transcripts (Figure 2e) .

EVs still remain unknown, we hypothesize that secretion of these EVs reflects the . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted October 16, 2020. . https://doi.org/10.1101/2020.10.14.20212340 doi: medRxiv preprint calcium-dependent intracellular protease that maintains the level of matrix which has crucial functions in coagulation (P<0.05) (Figure 3) . Reports of widespread . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted October 16, 2020. . https://doi.org/10.1101/2020.10.14.20212340 doi: medRxiv preprint

The Cluster 4 components ALT, RNU2-29P, SNORD33, miR-122-5p, and inflammation has also been found to stimulate secretion of SNORD33 packaged into 3 7 8 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted October 16, 2020. . https://doi.org/10.1101/2020.10.14.20212340 doi: medRxiv preprint proteins and exRNAs in patient sera clearly reflect specific host reactions to Group 1 than in Group 2 suggests that these proteins could have antiviral effects. deterioration. Our results also suggest that, in addition to their predictive value, . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted October 16, 2020. . https://doi.org/10.1101/2020.10.14.20212340 doi: medRxiv preprint 2 8 4 2 9

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted October 16, 2020. . https://doi.org/10.1101/2020.10.14.20212340 doi: medRxiv preprint consent was provided by all healthy donors before sample acquisition, in accordance . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted October 16, 2020. International Space Medical Co., Ltd. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted October 16, 2020. Immunity 53, 19-25 (2020). . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted October 16, 2020. . https://doi.org/10.1101/2020.10.14.20212340 doi: medRxiv preprint 

Functional delivery of viral miRNAs via exosomes

markers we have identified. An expanded random sample across all genders and ages 3 8 9should be more representative of the general population, and larger clinical studies are 3 9 0 required to validate the potential of these biomarkers for predicting the severity of disease. Indeed, biomarkers such as PRKCB, COPB2, and CD147 may be involved in 3 9 5